阿帕替尼联合TACE治疗原发性肝癌的临床研究

Apatinib combined with TACE in the treatment of primary liver cancer

目的研究阿帕替尼联合经肝动脉化疗栓塞术(TACE)治疗中晚期原发性肝癌患者的临床效果。方法将40例中晚期原发性肝癌患者随机分为2组,分别接受TACE治疗(对照组,n=20)及TACE联合阿帕替尼治疗(观察组,n=20),对比2组在疾病控制率、半年生存率以及不良反应上的差异。结果观察组患者疾病控制率(65.0%)与对照组患者(30.0%)相比明显上升,存在统计学差异(P<0.05);观察组患者半年内生存率(65.0%)与对照组患者(45.0%)相比升高,但差异无统计学意义(P>0.05);观察组患者不良反应发生率与对照组患者相比存在统计学差异(P<0.05)。结论阿帕替尼联合TACE治疗原发性肝癌患者效果显著,安全性好,值得推广。

Objective To study the apatinib combined with TACE(transcatheter arterial chemoembolization)in the treatment of advanced primary liver cancer(clinical)patients.Methods 40 cases of advanced primary liver cancer patients were randomly divided into 2 groups,were treated with TACE(20 cases in the control group)and TACE combined with apatinib treatment(observation group 20 cases).The differences between two groups of control rate,survival rate and adverse reaction in disease.Results the rate of disease control in the observation group(65%)was significantly higher than that of the control group(30%),and the comparison was statistically significant(P<0.05).The survival rate of the patients in the observation group(65%)was higher than that of the control group(45%),and the difference was not statistically significant(P>0.05).The incidence of adverse reactions in the observation group was statistically significant compared with those in the control group(P<0.05).Conclusion apatinib combined with TACE in the treatment of primary liver cancer patients have significant effect,safety,and is worthy of promotion.